Navigation Links
Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation
Date:7/22/2008

Company to Launch Innovative Laser Lipolysis Technology in the European

Union

WESTFORD, Mass., July 22 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, has received the European CE Mark for Smartlipo MPX(TM), the company's high-powered, dual-wavelength aesthetic workstation to liquefy fat and tighten skin through collagen remodeling. The CE Mark certifies that the Smartlipo MPX conforms to the essential health and safety requirements of the European Medical Device Directive.

Cynosure expects to launch Smartlipo MPX through its subsidiaries in the European Union beginning this quarter. Cynosure has marketed and sold Smartlipo MPX in the United States since the second quarter of 2008.

"The quality associated with the Smartlipo brand is an important differentiator for Cynosure among U.S. customers and consumers, and we expect this to be equally true as we introduce Smartlipo MPX to the international market," said President and Chief Executive Officer Michael Davin. "We believe the integration of our MultiPlex(TM) technology and SmartSense(TM) intelligent delivery system makes Smartlipo MPX the ideal platform blending body sculpting and tissue tightening through coagulation. Together, these applications are forecast to help drive the global aesthetic market from $8.4 billion in 2007 to more than $15 billion by 2011(1). We expect that our continued focus on innovation will enable Cynosure to remain at the forefront of this high-growth market."

"The EU represents the next phase of our multi-pronged strategy to expand the geographic reach of our Smartlipo technology," Davin said. "Smartlipo MPX training for our European subsidiaries is already underway, and they are eager to introduce the product in their markets. This rollout will be followed by a targeted launch in select countries in the Middle East, as well as ongoing submissions for regulatory approvals in the Asia Pacific region."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations regarding the performance and market acceptance of the Smartlipo MPX and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market acceptance of the Smartlipo MPX, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, each of which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

(1) Medical Insight, Inc., Global Aesthetic Market Study (2007)


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
Breaking Medicine Technology:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... has partnered with Mediaplanet to help educate the many who are unaware of ... section dedicated to aphasia will run within the “Stroke Awareness” campaign. , The ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... students studying complementary medicine. Allison Outerbridge is this year’s Life University ... May 18 at the university’s Student Leadership Awards ceremony. , Outerbridge is approaching ...
(Date:5/26/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... Award for its use of effective workplace strategies to increase business and employee success. ... the Families and Work Institute (FWI) and the Society for Human Resource Management (SHRM), ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in ... 5, 2016, communities around the world will gather to recognize these cancer survivors as ... Day® is an annual worldwide Celebration of Life that is held on the first ...
Breaking Medicine News(10 mins):